Academic Journal
Q1Signal Transduction and Targeted Therapy
About Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy is a scholarly journal published by Springer Nature. SCImago 2025 places it in Q1 with an SJR of 17.74 and an H-index of 224.
Its listed coverage is 2016-2026 and its research categories include Cancer Research (Q1); Genetics (Q1). The 2025 dataset reports 423 documents and 58350 citations across the latest three-year reporting window.
Signal transduction and targeted therapy are revolutionizing the field of cancer treatment and other chronic diseases by offering a more precise and effective approach. Unlike traditional therapies, which often affect both healthy and diseased cells, targeted therapies interfere with specific molecular targets involved in disease progression. At the heart of these therapies lies the complex process of signal transduction—the method by which cells respond to external signals.
What is Signal Transduction?
Signal transduction is a series of biochemical processes through which a cell converts an external signal into a functional change. This process begins when signaling molecules, such as hormones or growth factors, bind to specific receptors on the cell surface. These receptors then activate a cascade of intracellular signals, often involving kinases, enzymes, or secondary messengers, which ultimately lead to cellular responses like growth, division, differentiation, or apoptosis.
Aberrations in signal transduction pathways can lead to uncontrolled cell growth and cancer. For instance, mutations in genes encoding growth factor receptors or downstream signaling molecules can cause constant activation of these pathways, even in the absence of external signals.
Targeted Therapy: Precision Treatment
Targeted therapy aims to block these abnormal signaling pathways that drive disease. Unlike chemotherapy, which affects rapidly dividing cells indiscriminately, targeted therapy is designed to interfere with specific molecules necessary for tumor growth and survival.
Some common targets include:
-
EGFR (Epidermal Growth Factor Receptor): Overexpressed in several cancers, including lung and colorectal cancer.
-
HER2 (Human Epidermal Growth Factor Receptor 2): A key target in breast cancer.
-
BRAF and MEK proteins: Often mutated in melanoma.
-
VEGF (Vascular Endothelial Growth Factor): Involved in the formation of new blood vessels (angiogenesis) that support tumor growth.
By inhibiting these pathways, targeted therapies can slow or stop disease progression with fewer side effects compared to conventional treatments.
Types of Targeted Therapies
-
Monoclonal Antibodies – Engineered proteins that bind to specific antigens on the surface of cancer cells, blocking growth signals or marking cells for immune destruction.
-
Small Molecule Inhibitors – These penetrate the cell and block enzymes or proteins involved in signal transduction, such as tyrosine kinase inhibitors (TKIs).
-
Hormone Therapies – Target hormone-sensitive cancers like breast and prostate cancer by interfering with hormone signaling pathways.
Benefits and Limitations
Targeted therapy has shown great promise in improving survival rates and quality of life. However, not all patients respond equally, and resistance can develop over time. Therefore, biomarker testing and personalized medicine are crucial for selecting the right therapy for each individual.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Signal transduction and targeted therapy are rapidly evolving fields in biomedical research and clinical medicine, with significant implications for disease treatment, especially in oncology. These approaches focus on understanding and intervening in the cellular communication pathways that regulate growth, survival, and differentiation, offering new hope for more precise and effective treatments.
What is Signal Transduction?
Signal transduction refers to the process by which cells respond to external stimuli through a series of molecular events, typically involving protein interactions and phosphorylation cascades. These pathways transmit signals from the cell surface to the nucleus, resulting in changes in gene expression and cellular behavior. Dysregulation of these pathways is a hallmark of many diseases, including cancer, autoimmune disorders, and neurodegenerative conditions.
Common signal transduction pathways include the MAPK/ERK, PI3K/AKT, and JAK/STAT pathways. Aberrant activation of these signaling networks can lead to uncontrolled cell proliferation and survival, making them critical targets for therapeutic intervention.
Rise of Targeted Therapy in Modern Medicine
Targeted therapy is a form of precision medicine that specifically inhibits molecules involved in signal transduction pathways driving disease progression. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, targeted therapies are designed to interfere with specific molecular targets, reducing side effects and improving outcomes.
For example, tyrosine kinase inhibitors (TKIs) like imatinib have revolutionized the treatment of chronic myeloid leukemia by blocking the BCR-ABL fusion protein. Similarly, HER2 inhibitors such as trastuzumab are effective in HER2-positive breast cancer by targeting the HER2 receptor involved in cell signaling.
Expanding Applications Beyond Cancer
While targeted therapy is most commonly associated with cancer treatment, its scope is expanding. Researchers are exploring targeted approaches for inflammatory diseases, cardiovascular conditions, and even rare genetic disorders. Drugs that inhibit Janus kinases (JAKs) have shown promise in treating rheumatoid arthritis and other autoimmune diseases by modulating cytokine signaling.
Furthermore, combining targeted therapies with immunotherapies, such as checkpoint inhibitors, is opening new avenues in cancer treatment, enhancing the immune system’s ability to recognize and destroy tumor cells.
Challenges and Future Directions
Despite the promise, challenges remain in signal transduction and targeted therapy. Drug resistance, tumor heterogeneity, and the complexity of signaling networks can limit long-term efficacy. However, advancements in genomics, proteomics, and bioinformatics are enabling better identification of therapeutic targets and biomarkers, allowing for more personalized treatment strategies.
Emerging technologies like CRISPR gene editing, nanotechnology, and AI-driven drug discovery are also playing a crucial role in accelerating the development of next-generation targeted therapies.
Recent Research Articles
Latest publications matched automatically by ISSN.
Reviews
Community Reviews
Version History
April 13, 2025 at 12:12 pm
April 13, 2025